Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury … – Seeking Alpha
|
Asterias Bio's stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury …
Seeking Alpha Asterias Biotherapeutics (AST +2.7%) announces positive results from the Phase 1/2 SCiStar study assessing AST-OPC1 in patients with subacute motor complete spinal cord injury. Results at month 12 showed 67% of those with AIS-A-categorized injury … |
